Data / Drug companies / Puracap Laboratories LLC DBA Blu Pharmaceuticals
Puracap Laboratories LLC DBA Blu Pharmaceuticals: 46 products in the FDA NDC directory, labeler code 24658
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Puracap Laboratories LLC DBA Blu Pharmaceuticals (labeler code 24658) lists 46 products in the FDA National Drug Code Directory, covering 21 finished drugs by generic name. By type: 46 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on July 28, 2026.
The request: Watch Puracap Laboratories LLC DBA Blu Pharmaceuticals (FDA labeler code 24658): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 24658
- Products in commercial distribution
- 46
- Packages
- 81
- Finished drugs by generic name
- 21
- Prescription products
- 46
- Over the counter products
- 0
- Flagged as original packager
- 46 of 46 products that carry the flag
- Started marketing in the last 12 months
- 3
- Earliest marketing start
- April 1, 2016
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 46 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 46 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 13 | 28.3% |
| Tablet, film coated | 11 | 23.9% |
| Capsule | 11 | 23.9% |
| Powder, for suspension | 7 | 15.2% |
| Capsule, extended release | 3 | 6.5% |
| Capsule, liquid filled | 1 | 2.2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Venlafaxine Hydrochloride | 24658-127 | Capsule, extended release | Generic drugs (ANDA) | July 28, 2026 |
| Venlafaxine Hydrochloride | 24658-126 | Capsule, extended release | Generic drugs (ANDA) | July 28, 2026 |
| Venlafaxine Hydrochloride | 24658-125 | Capsule, extended release | Generic drugs (ANDA) | July 28, 2026 |
| Azithromycin | 24658-707 | Powder, for suspension | Generic drugs (ANDA) | May 30, 2025 |
| Doxycycline Hyclate | 24658-310 | Tablet, film coated | Generic drugs (ANDA) | March 7, 2025 |
| Rosuvastatin calcium | 24658-264 | Tablet | Generic drugs (ANDA) | August 23, 2023 |
| Rosuvastatin calcium | 24658-263 | Tablet | Generic drugs (ANDA) | August 23, 2023 |
| Rosuvastatin calcium | 24658-262 | Tablet | Generic drugs (ANDA) | August 23, 2023 |
| Rosuvastatin calcium | 24658-261 | Tablet | Generic drugs (ANDA) | August 23, 2023 |
| Rifampin | 24658-802 | Capsule | Generic drugs (ANDA) | March 14, 2023 |
| Rifampin | 24658-801 | Capsule | Generic drugs (ANDA) | March 14, 2023 |
| Doxepin Hydrochloride | 24658-797 | Capsule | Generic drugs (ANDA) | March 14, 2023 |
| Doxepin Hydrochloride | 24658-796 | Capsule | Generic drugs (ANDA) | March 14, 2023 |
| Doxepin Hydrochloride | 24658-795 | Capsule | Generic drugs (ANDA) | March 14, 2023 |
| Doxepin Hydrochloride | 24658-794 | Capsule | Generic drugs (ANDA) | March 14, 2023 |
| Doxepin Hydrochloride | 24658-793 | Capsule | Generic drugs (ANDA) | March 14, 2023 |
| Cholestyramine light | 24658-271 | Powder, for suspension | Generic drugs (ANDA) | March 14, 2023 |
| Cholestyramine light | 24658-270 | Powder, for suspension | Generic drugs (ANDA) | March 14, 2023 |
| Cholestyramine | 24658-266 | Powder, for suspension | Generic drugs (ANDA) | March 14, 2023 |
| Aminocaproic acid | 24658-799 | Tablet | Generic drugs (ANDA) | January 24, 2023 |
| Aminocaproic acid | 24658-798 | Tablet | Generic drugs (ANDA) | January 24, 2023 |
| Ursodiol | 24658-999 | Capsule | Generic drugs (ANDA) | September 30, 2021 |
| Estradiol | 24658-704 | Tablet | Generic drugs (ANDA) | September 10, 2021 |
| Estradiol | 24658-703 | Tablet | Generic drugs (ANDA) | September 10, 2021 |
| Estradiol | 24658-702 | Tablet | Generic drugs (ANDA) | September 10, 2021 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.